カテゴリ： GlobalData, アメリカ, 企業調査

Sangamo Therapeutics Inc (SGMO)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Sangamo Therapeutics Inc (SGMO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10095
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：75
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Sangamo Therapeutics Inc (Sangamo), formerly Sangamo BioSciences Inc, is a clinical stage biotechnology company that focuses on the research, development and commercialization of engineered DNA-binding proteins (ZFPs) for gene regulation, cell therapy and therapeutic genome editing. Its product candidates targets the treatment of HIV/AIDS, hemophilia A and B, hurler syndrome (MPS I), fabry disease, Huntington’s disease and many others. Its ZFPs based products are used in various applications such as human therapeutics, research reagents, pharmaceutical protein production, plant agriculture, cell-line engineering and production of transgenic animals. The company has presence in the UK and the US. Sangamo is headquartered in Richmond, California, the US.

Sangamo Therapeutics Inc (SGMO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Licensing Agreements 12
Kite Pharma to Enter into Licensing Agreement with Sangamo Therapeutics 12
Sangamo Therapeutics Enters into Licensing Agreement with Pfizer 14
Pfizer Enters into Licensing Agreement with Sangamo Therapeutics 15
Biogen Idec Enters into Licensing Agreement with Sangamo BioSciences for Hemoglobinopathies Therapeutics 16
Shire Amends Licensing Agreement with Sangamo BioSciences for ZFP Therapeutics 17
Sangamo BioSciences Enters into Licensing Agreement for mRNA Delivery Technology 19
Equity Offering 20
Sangamo Therapeutics Raises USD230 Million in Public Offering of Shares 20
Sangamo BioSciences Raises USD72.5 Million in Public Offering of Shares 22
Sangamo Therapeutics Raises USD83.4 Million in Public Offering of Shares 24
Sangamo BioSciences Completes Public Offering Of Shares For US$100 Million 26
Sangamo BioSciences Completes Public Offering Of Shares For US$74.2 Million 28
Asset Transactions 30
Bioverativ to Acquire Rights to Genome Editing Program from Sangamo BioSciences 30
Acquisition 31
Sangamo Therapeutics Acquires TxCell 31
Sangamo BioSciences Completes Acquisition Of Ceregene, Biotechnology Company 33
Sangamo Therapeutics Inc – Key Competitors 35
Sangamo Therapeutics Inc – Key Employees 36
Sangamo Therapeutics Inc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Strategy And Business Planning 38
Nov 09, 2017: Sangamo Announces Plans For New Headquarters In Brisbane, California 38
Financial Announcements 39
Aug 08, 2018: Sangamo Therapeutics reports second quarter 2018 financial results 39
May 08, 2018: Sangamo Therapeutics Reports First Quarter 2018 Financial Results 41
Feb 21, 2018: Sangamo Therapeutics Reports Fourth Quarter And Full Year 2017 Financial Results 43
Nov 09, 2017: Sangamo Therapeutics Reports Third Quarter 2017 Financial Results 45
Aug 09, 2017: Sangamo Therapeutics Reports Second Quarter 2017 Financial Results 47
May 10, 2017: Sangamo Therapeutics Reports First Quarter 2017 Financial Results 49
Feb 28, 2017: Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results 50
Feb 27, 2017: Sangamo Therapeutics Announces Chief Financial Officer Succession 52
Corporate Communications 53
Jun 28, 2018: Sangamo Therapeutics Appoints Karen Smith to its Board of Directors 53
May 03, 2018: Sangamo Therapeutics Announces Senior Leadership Changes 54
Feb 12, 2018: Sangamo Therapeutics Appoints Heather D. Turner As Senior Vice President And General Counsel 55
Jun 29, 2017: Sangamo Therapeutics Appoints Roger Jeffs, Ph.D. and Joseph S. Zakrzewski to its Board of Directors 56
Apr 25, 2017: Sangamo Announces The Retirement Of Its Founder And Genome Editing Pioneer Edward Lanphier From The Board Of Directors 57
Legal and Regulatory 58
Aug 23, 2018: SEC Charges Former Pharma Executive and Others with Insider Trading 58
Government and Public Interest 59
Apr 27, 2018: Therapies Targeting Cancer, Deadly Immune Disorder and Life-Threatening Blood Condition Get Almost $32 Million Boost from Stem Cell Agency 59
Product News 61
11/01/2017: Bioverativ to Present New Data on ST-400 at ASH 2017 Annual Meeting 61
10/17/2017: Sangamo Therapeutics Announces Presentations At 2017 Annual Congress Of The European Society Of Gene And Cell Therapy 62
08/25/2017: Sangamo And Pfizer Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial Evaluating SB-525 Investigational Gene Therapy For Hemophilia A 63
04/27/2018: Sangamo Announces $8 Million CIRM Grant For ST-400 — A Gene-Edited Cell Therapy Candidate — To Treat Transfusion-Dependent Beta-Thalassemia 64
Product Approvals 65
Oct 02, 2017: Sangamo And Bioverativ Announce FDA Acceptance of IND Application For ST-400 – A Gene-Edited Cell Therapy Candidate – to Treat Beta-Thalassemia 65
Jun 07, 2017: Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency 66
May 16, 2017: Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy 67
May 04, 2017: Sangamo Therapeutics Announces Orphan Drug Designation for SB-525 cDNA Gene Therapy for Hemophilia A 68
Feb 27, 2017: Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For SB-318 In Vivo Genome Editing Therapeutic For MPS I 69
Jan 11, 2017: Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-318 Genome Editing Treatment for MPS I 70
Jan 05, 2017: Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A 71
Clinical Trials 72
Feb 08, 2017: Sangamo Therapeutics Announces Data on SB-318 at The 13th Annual WORLDSymposium Meeting 72
Feb 08, 2017: Sangamo Therapeutics Announces Data on SB-913 at The 13th Annual WORLDSymposium Meeting 73
Other Significant Developments 74
Jan 06, 2017: Sangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus On Clinical Development Of Genomic Therapies 74
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75

List of Tables
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sangamo Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Kite Pharma to Enter into Licensing Agreement with Sangamo Therapeutics 12
Sangamo Therapeutics Enters into Licensing Agreement with Pfizer 14
Pfizer Enters into Licensing Agreement with Sangamo Therapeutics 15
Biogen Idec Enters into Licensing Agreement with Sangamo BioSciences for Hemoglobinopathies Therapeutics 16
Shire Amends Licensing Agreement with Sangamo BioSciences for ZFP Therapeutics 17
Sangamo BioSciences Enters into Licensing Agreement for mRNA Delivery Technology 19
Sangamo Therapeutics Raises USD230 Million in Public Offering of Shares 20
Sangamo BioSciences Raises USD72.5 Million in Public Offering of Shares 22
Sangamo Therapeutics Raises USD83.4 Million in Public Offering of Shares 24
Sangamo BioSciences Completes Public Offering Of Shares For US$100 Million 26
Sangamo BioSciences Completes Public Offering Of Shares For US$74.2 Million 28
Bioverativ to Acquire Rights to Genome Editing Program from Sangamo BioSciences 30
Sangamo Therapeutics Acquires TxCell 31
Sangamo BioSciences Completes Acquisition Of Ceregene, Biotechnology Company 33
Sangamo Therapeutics Inc, Key Competitors 35
Sangamo Therapeutics Inc, Key Employees 36
Sangamo Therapeutics Inc, Subsidiaries 37

List of Figures
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Sangamo Therapeutics Inc (SGMO)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Aetna Inc：戦略・SWOT・企業財務分析
    Aetna Inc - Strategy, SWOT and Corporate Finance Report Summary Aetna Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Bank of the West：企業の戦略・SWOT・財務情報
    Bank of the West - Strategy, SWOT and Corporate Finance Report Summary Bank of the West - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • CARBO Ceramics Inc (CRR)：企業の財務・戦略的SWOT分析
    CARBO Ceramics Inc (CRR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Boralex Inc (BLX)：電力：M&Aディール及び事業提携情報
    Summary Boralex Inc (Boralex) is a renewable energy company. It develops, builds, and operates renewable energy power facilities. The company’s asset portfolio includes wind, hydro, thermal, and solar projects. Boralex also has interests in various projects under development stages. Under long-term …
  • Phoenix Pharmahandel GmbH & Co KG：企業の戦略的SWOT分析
    Phoenix Pharmahandel GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Springs Global Participacoes S.A.：企業の戦略・SWOT・財務情報
    Springs Global Participacoes S.A. - Strategy, SWOT and Corporate Finance Report Summary Springs Global Participacoes S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Kyivstar JSC：企業の戦略的SWOT分析
    Kyivstar JSC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Broadwind Energy Inc (BWEN)：企業の財務・戦略的SWOT分析
    Broadwind Energy Inc (BWEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Naftna industrija Srbije ad (NIIS)：企業の財務・戦略的SWOT分析
    Naftna industrija Srbije ad (NIIS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Stem Inc：電力：M&Aディール及び事業提携情報
    Summary Stem, Inc. (Stem) is a provider of energy storage solutions and software to businesses for managing energy costs. It leverages big data, predictive analytics, cloud computing, and advanced energy storage to reduce peak electrical usage, lower electric bills, and eliminate the need for new ge …
  • JEA：企業の戦略的SWOT分析
    JEA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This up- …
  • Big Rock Brewery, Inc.：企業の戦略・SWOT・財務情報
    Big Rock Brewery, Inc. - Strategy, SWOT and Corporate Finance Report Summary Big Rock Brewery, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • InSightec Ltd：製品パイプライン分析
    Summary Insightec Ltd (InSightec), a subsidiary of Elbit Imaging Ltd is a medical device company that develops and markets MR ultrasound based medical devices. The company offers products through divisions such as neurosurgery, oncology and womens’ health. It offers services including commercial dev …
  • LA DORIA S.p.A.：企業の戦略・SWOT・財務情報
    LA DORIA S.p.A. - Strategy, SWOT and Corporate Finance Report Summary LA DORIA S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Suzuken Co Ltd (9987)：企業の財務・戦略的SWOT分析
    Suzuken Co Ltd (9987) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Britannia Industries Ltd (BRITANNIA)：企業の財務・戦略的SWOT分析
    Britannia Industries Ltd (BRITANNIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Cincinnati Bell Inc (CBB)：企業の財務・戦略的SWOT分析
    Cincinnati Bell Inc (CBB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Herbalife Nutrition Ltd (HLF)：企業の財務・戦略的SWOT分析
    Herbalife Nutrition Ltd (HLF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Australian Postal Corporation：企業の戦略・SWOT・財務分析
    Australian Postal Corporation - Strategy, SWOT and Corporate Finance Report Summary Australian Postal Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Max-Delbruck-Centrum fur Molekulare Medizin (MDC)-製薬・医療分野：企業M&A・提携分析
    Summary Max-Delbruck-Centrum fur Molekulare Medizin (MDC) is a biomedical research centre. The centre offers molecular biology research services, signal transduction research, development biology research, molecular immunology and gene therapy research, non coding RNAs research, cytoplasmic gene reg …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆